Alliance Global Partners lowered the firm’s price target on Lipocine (LPCN) to $6.75 from $10 and keeps a Buy rating on the shares after the company reported Q4 earnings that the firm says “were optically strong but fundamentally as expected.” The firm’s reduced target reflects LPCN 1154 delays after the company said LPCN 1154 has been delayed by about two years due to requirements for a safety/efficacy trial, the analyst noted.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPCN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue